Published in Nat Rev Cancer on August 01, 2005
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet (2010) 4.27
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol (2009) 3.96
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell (2010) 3.28
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci U S A (2007) 2.30
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
Genetic consequences of programmed genome rearrangement. Curr Biol (2012) 2.16
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
The blood-testis barrier and its implications for male contraception. Pharmacol Rev (2011) 2.10
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Genetic regulators of a pluripotent adult stem cell system in planarians identified by RNAi and clonal analysis. Cell Stem Cell (2012) 2.03
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Chromosomal redistribution of male-biased genes in mammalian evolution with two bursts of gene gain on the X chromosome. PLoS Biol (2010) 1.98
Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell (2015) 1.91
DNA methylation dynamics during the mammalian life cycle. Philos Trans R Soc Lond B Biol Sci (2013) 1.85
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica (2010) 1.80
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
Biology and regulation of ectoplasmic specialization, an atypical adherens junction type, in the testis. Biochim Biophys Acta (2007) 1.74
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem (2011) 1.68
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood (2013) 1.63
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Promoter DNA methylation couples genome-defence mechanisms to epigenetic reprogramming in the mouse germline. Development (2012) 1.55
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Oncogenic transformation of Drosophila somatic cells induces a functional piRNA pathway. Genes Dev (2016) 1.47
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun (2007) 1.46
Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A (2009) 1.45
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
Mechanisms and evolutionary patterns of mammalian and avian dosage compensation. PLoS Biol (2012) 1.43
Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS One (2016) 1.41
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
Dnmt3b recruitment through E2F6 transcriptional repressor mediates germ-line gene silencing in murine somatic tissues. Proc Natl Acad Sci U S A (2010) 1.37
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 1.32
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. Oncotarget (2012) 1.31
Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer (2013) 1.30
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One (2011) 1.29
Genome-wide expression of azoospermia testes demonstrates a specific profile and implicates ART3 in genetic susceptibility. PLoS Genet (2008) 1.28
A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics (2007) 1.27
Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics (2010) 1.27
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica (2009) 1.27
Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics (2007) 1.26
Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 1.26
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol (2011) 1.24
Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell biology. Am J Pathol (2009) 1.22
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy (2009) 1.21
The expansion of the PRAME gene family in Eutheria. PLoS One (2011) 1.21
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun (2007) 1.21
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
Dissecting the first transcriptional divergence during human embryonic development. Stem Cell Rev (2012) 1.20
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun (2007) 1.20
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. Oncoscience (2014) 1.17
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Epiblast/germ line hypothesis of cancer development revisited: lesson from the presence of Oct-4+ cells in adult tissues. Stem Cell Rev (2010) 1.17
Immunotherapy for metastatic solid cancers. Adv Surg (2011) 1.16
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis (2011) 1.16
Regulation of spermiogenesis, spermiation and blood-testis barrier dynamics: novel insights from studies on Eps8 and Arp3. Biochem J (2011) 1.15
Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res (2009) 1.15
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One (2009) 1.14
The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet (2008) 1.14
Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res (2009) 1.14
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res (2011) 1.14
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 1.13
Novel dimensions of piRNAs in cancer. Cancer Lett (2013) 1.13
PIWI Expression and Function in Cancer. Front Genet (2012) 1.12
Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung (2009) 1.12
Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int (2006) 1.11
Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol (2012) 1.10
Drosophila cancer models. Dev Dyn (2011) 1.10
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3. PLoS Genet (2013) 1.09
Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res (2010) 1.09
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother (2011) 1.08
Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One (2012) 1.08
Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol (2008) 1.07
A transcriptomic analysis of human centromeric and pericentric sequences in normal and tumor cells. Nucleic Acids Res (2009) 1.07
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol (2007) 2.68
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res (2008) 2.14
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer (2008) 1.54
Autoantibodies against cancer antigens. Methods Mol Biol (2009) 1.54
Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. Int J Cancer (2011) 1.52
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol (2012) 1.51
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol (2009) 1.51
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res (2012) 1.49
The SSX gene family: characterization of 9 complete genes. Int J Cancer (2002) 1.46
Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A (2010) 1.46
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res (2002) 1.46
Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A (2009) 1.45
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res (2004) 1.44
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods (2008) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood (2006) 1.41
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest (2006) 1.41
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med (2013) 1.40
Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A (2005) 1.39
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A (2002) 1.38
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood (2005) 1.38
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res (2005) 1.36
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 1.33
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun (2003) 1.32
Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer (2003) 1.31
Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer (2002) 1.31